A PET study of 18FDG uptake in soft tissue masses

被引:248
作者
Lodge, MA
Lucas, JD
Marsden, PK
Cronin, BF
O'Doherty, MJ
Smith, MA
机构
[1] United Med & Dent Sch Guys & St Thomas Hosp, Div Radiol Sci, Clin PET Ctr, London SE1 9RT, England
[2] Guys Hosp, Dept Orthopaed, London SE1 9RT, England
[3] St Thomas Hosp, Dept Orthopaed, London, England
关键词
positron emission tomography; 2-[F-18]-fluoro-2-deoxy-D-glucose; soft tissue sarcoma;
D O I
10.1007/s002590050355
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
A study was performed with the aim of investigating some of the methodological factors affecting the ability of quantitative 2-[F-18] -fluoro-2-deoxy-D-glucose (FDG) positron emission tomography to assess tumour malignancy. Twenty-nine patients with soft tissue masses were studied using a 6-hour scanning protocol and various indices of glucose metabolism were compared with histological grade. Significant differences were observed in the time-activity response of benign and high-grade tumours. High-grade sarcomas were found to reach a peak activity concentration approximately 4 h after injection whereas benign lesions reached a maximum within 30 min. This translated to improved differentiation between these two tumour types using a standard uptake value (SUV) derived from images acquired at later times. An SUV measured 4 h post-injection was found to be as useful an index of tumour malignancy as the metabolic rate of FDG determined using either Patlak or non-linear regression techniques. Each of these indices had a sensitivity and specificity of 100% and 76% respectively for the discrimination of high-grade sarcomas from benign tumours.
引用
收藏
页码:22 / 30
页数:9
相关论文
共 20 条
[1]  
ADLER LP, 1991, J NUCL MED, V32, P1508
[2]   GRADING LIPOSARCOMAS WITH PET USING [F-18] FDG [J].
ADLER, LP ;
BLAIR, HF ;
WILLIAMS, RP ;
PATHRIA, MN ;
MAKLEY, JT ;
JOYCE, MJ ;
ALKAISI, N ;
MIRALDI, F .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1990, 14 (06) :960-962
[3]   Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology? [J].
Brock, CS ;
Meikle, SR ;
Price, P .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1997, 24 (06) :691-705
[4]  
Eary JF, 1998, J NUCL MED, V39, P250
[5]  
Eary JF, 1998, CLIN CANCER RES, V4, P1215
[6]   CHARACTERISTICS OF A NEW AUTOMATED BLOOD-SAMPLING SYSTEM FOR POSITRON EMISSION TOMOGRAPHY [J].
ERIKSSON, L ;
INGVAR, M ;
ROSENQVIST, G .
IEEE TRANSACTIONS ON NUCLEAR SCIENCE, 1995, 42 (04) :1007-1011
[7]   PET EVALUATION OF SOFT-TISSUE MASSES WITH F-18 FLUORO-2-DEOXY-D-GLUCOSE [J].
GRIFFETH, LK ;
DEHDASHTI, F ;
MCGUIRE, AH ;
MCGUIRE, DJ ;
PERRY, DJ ;
MOERLEIN, SM ;
SIEGEL, BA .
RADIOLOGY, 1992, 182 (01) :185-194
[8]  
HAMACHER K, 1986, J NUCL MED, V27, P235
[9]  
HAMBERG LM, 1994, J NUCL MED, V35, P1308
[10]   CANCER-DETECTION WITH WHOLE-BODY PET USING 2-[F-18]FLUORO-2-DEOXY-D-GLUCOSE [J].
HOH, CK ;
HAWKINS, RA ;
GLASPY, JA ;
DAHLBOM, M ;
TSE, NY ;
HOFFMAN, EJ ;
SCHIEPERS, C ;
CHOI, Y ;
REGE, S ;
NITZSCHE, E ;
MADDAHI, J ;
PHELPS, ME .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1993, 17 (04) :582-589